BTX306
BTX306 is a cereblon-targeting molecular glue degrader. BTX306 reduces myeloma cell viability and induces apoptosis. BTX306 overcomes myeloma cell resistance to Lenalidomide or Bortezomib (HY-10227). BTX306 is active against primary myeloma cells, and shows efficacy in vivo. BTX306 can be used for myeloma research[1].
Product Specifications
CAS Number
2230747-62-1
UNSPSC
12352005
Target
Apoptosis; Caspase; Molecular Glues
Related Pathways
Apoptosis; PROTAC
Field of Research
Cancer
Smiles
CC1=CC=C(C=C1Cl)NC(NCC2=C3CN(C(C3=CS2)=O)C4CCC(NC4=O)=O)=O
Molecular Formula
C20H19ClN4O4S
Molecular Weight
446.91
References & Citations
[1]Zou J, et al. The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance. J Mol Med (Berl) . 2020 Aug;98 (8) :1161-1173.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
